Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$32.95

0.64 (1.98%)

07:09
02/14/19
02/14
07:09
02/14/19
07:09

Alkermes reports Q4 EPS 34c, consensus (5c)

Reports Q4 revenue $315.8M, consensus $255.09M. "Our strong financial results in 2018 were driven by the growth of our proprietary commercial products and the continued strength and diversity of our royalty and manufacturing business. As we enter 2019, our financial expectations reflect the continued growth of our proprietary products, VIVITROL and ARISTADA, as well as important investments in the future growth drivers of the company including our advancing development pipeline and commercial capabilities to support our expanding presence in schizophrenia," said CFO James Frates.

  • 14

    Feb

ALKS Alkermes
$32.95

0.64 (1.98%)

01/02/19
CANT
01/02/19
NO CHANGE
Target $33
CANT
Neutral
Alkermes lacks meaningful pipeline catalysts in 2019, says Cantor Fitzgerald
Despite being down 60% from its 2018 highs, the risk/reward on Alkermes is adequately reflected in the current stock price, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst says upside to his forecasts and rating could come from ALKS 4230, the company's early immune-oncology candidate. However, he believes near term risk could come from pipeline failures, or Vivitrol and Aristada revenue coming in below consensus estimates. Folkes sees no new meaningful pipeline catalysts in 2019 to get him off the sidelines with respect to shares. As such, he reiterates a Neutral rating on Alkermes with a $33 price target.
01/22/19
JEFF
01/22/19
NO CHANGE
Target $43
JEFF
Hold
Doctors find Alkermes schizophrenia data 'somewhat' meaningful, says Jefferies
Jefferies analyst Biren Amin says his firm performed a second survey of 35 practicing psychiatrists who treat adult schizophrenia following the Enlighten-2 readout from Alkermes. Doctors appear to find the Phase 3 data "somewhat clinically meaningful," with a majority of potential prescriptions for ALKS 3831 converting from olanzapine and other atypicals in 2021, Amin tells investors in a research note. The survey shows that by 2021, about 13% of patients would be prescribed ALKS 3831, with about 50% of its share coming from conversion from other atypicals and 40% coming from olanzapine. The analyst adds that he did not take into account the potential influence of a branded price, which he notes could affect uptake. Amin has a Hold rating on Alkermes with a $43 price target.
02/04/19
STFL
02/04/19
NO CHANGE
STFL
Hold
Alkermes receipt of CRL for 5461 'no surprise,' says Stifel
Stifel analyst Paul Matteis said it came as "no surprise" that the FDA issued a Complete Response Letter to Alkermes related to the company's new drug application for ALKS 5461 for major depressive disorder given the "highly critical advisory committee meeting" that preceded it. Following that "tumultuous adcomm meeting," he had removed any near-term credit for 5461 from his model and Matteis believes that credit for the asset is largely out of other analysts' models as well, he tells investors. While the company is already running a phase 3b trial, which could possibly be supportive of registration, Matteis said he is unsure if the FDA has explicitly signed-off on the design and approach. He keeps a Hold rating on Alkermes shares.
02/07/19
CANT
02/07/19
NO CHANGE
Target $33
CANT
Neutral
Mylan patent challenge on Tecfidera potential positive for Alkermes, says Cantor
Cantor Fitzgerald analyst Brandon Folkes views the institution of Mylan's (MYL) inter partes review challenge of Tecfidera's '514 patent as a potential positive for Alkermes (ALKS). The analyst has assumed Biogen's (BIIB) Tecfidera '514 patent holds through 2028, and thus had ascribed a "more-modest" value to Alkermes' royalty from BIIB098 sales. If Mylan is successful in its IPR challenge, says the analyst, it could provide $4-$7 per share upside to his current Alkermes price target of $33. Biogen reported Tecfidera revenues of $4.3B for 2018, $3.3B of which was generated in the U.S. Alkermes is entitled to a mid-teen royalty on worldwide sales of BIIB098, Folkes tells investors in a research note titled "Giving ALKS a Hall Pass to Support the Away Team This Time." However, he believes the market has discounted the contribution of the BIIB098 royalty to Alkermes, "given the uncertainty about how the product may be included in a Tecfidera life cycle extension given the '514 patent runs to 2028."

TODAY'S FREE FLY STORIES

SPN

Superior Energy

$4.43

0.165 (3.87%)

16:53
02/18/19
02/18
16:53
02/18/19
16:53
Earnings
Superior Energy reports Q4 EPS ($4.85), may not compare consensus (0.28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

MSG

Madison Square Garden

$291.37

0.85 (0.29%)

16:46
02/18/19
02/18
16:46
02/18/19
16:46
Periodicals
MSG denies Knicks sale talks after Bill Simmons claims otherwise »

Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

16:45
02/18/19
02/18
16:45
02/18/19
16:45
Hot Stocks
Windstream postpones release of Q4, FY18 financial results »

Windstream announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

UFPI

Universal Forest

$32.22

0.36 (1.13%)

16:43
02/18/19
02/18
16:43
02/18/19
16:43
Hot Stocks
Universal Forest signs agreement to acquire Wolverine Wood Products »

Universal Forest Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:36
02/18/19
02/18
16:36
02/18/19
16:36
Earnings
Breaking Earnings news story on Service Corp. »

Service Corp. sees FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

SCI

Service Corp.

$45.96

0.56 (1.23%)

16:34
02/18/19
02/18
16:34
02/18/19
16:34
Earnings
Service Corp. reports Q4 adjusted EPS 54c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

APY

Apergy

$36.84

0.92 (2.56%)

16:27
02/18/19
02/18
16:27
02/18/19
16:27
Earnings
Apergy reports Q4 adjusted EPS 36c, consensus 33c »

Reports Q4 revenue of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NAVI

Navient

$11.75

0.12 (1.03%)

16:20
02/18/19
02/18
16:20
02/18/19
16:20
Hot Stocks
Navient rejects highly conditional unsolicited 'expression of interest' »

Navient announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLCA

U.S. Silica

$14.41

-0.005 (-0.03%)

16:15
02/18/19
02/18
16:15
02/18/19
16:15
Hot Stocks
24 SandBox Logistics patent claims invalidated »

Proppant Express…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 28

    May

JBHT

J.B. Hunt

$113.78

1.66 (1.48%)

16:12
02/18/19
02/18
16:12
02/18/19
16:12
Hot Stocks
J.B. Hunt completes acquisition of Cory 1st Choice Home Delivery »

J.B. Hunt announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 06

    Mar

CAT

Caterpillar

$136.21

3.575 (2.70%)

16:10
02/18/19
02/18
16:10
02/18/19
16:10
Hot Stocks
Caterpillar announces several officer moves »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

CUB

Cubic

$60.35

2.995 (5.22%)

16:07
02/18/19
02/18
16:07
02/18/19
16:07
Hot Stocks
Cubic announces semiannual dividend of 13.5c per share »

Cubic announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

HMC

Honda

$27.35

0.04 (0.15%)

13:11
02/18/19
02/18
13:11
02/18/19
13:11
Periodicals
Honda plan to close U.K. plant not due to Brexit, Reuters reports »

Honda plans to shut its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$27.35

0.04 (0.15%)

13:07
02/18/19
02/18
13:07
02/18/19
13:07
Periodicals
Honda to close U.K. car plant in 2022, Reuters reports »

Honda is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUNMF

Lundin Mining

$0.00

(0.00%)

13:04
02/18/19
02/18
13:04
02/18/19
13:04
Downgrade
Lundin Mining rating change at Goldman Sachs »

Lundin Mining downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVR

Chicago Rivet & Machine

$28.36

0.56 (2.01%)

12:38
02/18/19
02/18
12:38
02/18/19
12:38
Hot Stocks
Chicago Rivet & Machine announces increase in quarterly cash dividend to 22c »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

, XRX

Xerox

$30.46

0.63 (2.11%)

12:36
02/18/19
02/18
12:36
02/18/19
12:36
Hot Stocks
Quest Diagnostics names Gabrielle Wolfson senior VP, CIO »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$87.77

2.27 (2.66%)

XRX

Xerox

$30.46

0.63 (2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRDX

Surmodics

$56.79

3.09 (5.75%)

12:29
02/18/19
02/18
12:29
02/18/19
12:29
Hot Stocks
Surmodics announces appointment of Timothy Arens as CFO »

Surmodics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

CUB

Cubic

$60.35

2.995 (5.22%)

, IBM

IBM

$138.05

1.55 (1.14%)

12:28
02/18/19
02/18
12:28
02/18/19
12:28
Hot Stocks
Cubic names IBM, Microsoft executive Kevin Eagan as Senior VP, Chief Digital »

Cubic (CUB) announced the…

CUB

Cubic

$60.35

2.995 (5.22%)

IBM

IBM

$138.05

1.55 (1.14%)

MSFT

Microsoft

$108.19

1.35 (1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

CGUSY

Casino Guichard Perrachon

$0.00

(0.00%)

11:50
02/18/19
02/18
11:50
02/18/19
11:50
Downgrade
Casino Guichard Perrachon rating change at Deutsche Bank »

Casino Guichard…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPYYY

Centrica

$0.00

(0.00%)

11:46
02/18/19
02/18
11:46
02/18/19
11:46
Downgrade
Centrica rating change at Berenberg »

Centrica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
02/18/19
02/18
11:15
02/18/19
11:15
General news
FX Summary: AUD-JPY has been the biggest mover »

FX Summary: AUD-JPY has…

MSM

MSC Industrial

$86.24

0.81 (0.95%)

11:07
02/18/19
02/18
11:07
02/18/19
11:07
Hot Stocks
MSC Industrial reports patent issued for cost-savings documentation system »

As previously reported on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

08:35
02/18/19
02/18
08:35
02/18/19
08:35
General news
Oil Action: Front-month WTI crude futures are up 1.0% »

Oil Action: Front-month…

07:00
02/18/19
02/18
07:00
02/18/19
07:00
General news
FX Update: A Dollar softening theme took hold during the London AM session »

FX Update: A Dollar…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.